Will Lewis, CEO of New Jersey-based Insmed Incorporated, believes this year will be transformational for the company, not least because it has several parallel late-stage clinical programs reaching maturation.
With A Transformational Year Underway, Insmed Ramps Up
With a reliable source of revenue in Arikayce and two key pulmonary late-stage trials reading out, Insmed aims to keep its commercial momentum going.
